Search Results: Treatment + Colorectal Cancer + Stage 4 (7 results)
Treating Advanced MSI-High or dMMR Cancers Using the Targeted Therapy MOMA-341 Given Alone or In Combination with Standard Therapies
https://www.facingourrisk.org/research-clinical-trials/study/356/treating-advanced-msi-high-or-dmmr-cancers-using-the-targeted-therapy-moma-341-given-alone-or-in-combination-with-standard-therapies
Treatment
Treatment study for people with advanced or metastatic cancers
This trial will study the safety, tolerability, and initial effectiveness of MOMA-341, a new type of targeted therapy, alone or in combination with a standard chemotherapy (irinotecan) or together with an immunotherapy to treat people with advanced or metastatic cancers with certain types of mutations.
Treating Advanced or Metastatic Cancers with a New PARP1 Inhibitor (GS-0201) Alone or Combined with Other Drugs
https://www.facingourrisk.org/research-clinical-trials/study/350/treating-advanced-or-metastatic-cancers-with-the-new-parp-inhibitor-alone-or-combined-with-other-drugs
Treatment
Treatment study for people with advanced or metastatic solid tumors
The goal of this treatment study is to learn if the new drug GS-0201 is safe and can help treat people with different types of metastatic or advanced cancer. GS-0201 is a new drug that has not yet been approved for treatment of cancer. GS-0201 is a type of targeted therapy known as a PARP1 inhibitor.
Study of a New Treatment Called ONM-501 Alone and in Combination with Immunotherapy for Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas
https://www.facingourrisk.org/research-clinical-trials/study/311/study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas
Treatment
Treatment study for people with triple negative breast cancer, advanced solid tumors or lymphomas
This study is looking at the safety and best dose for treatment with the drug ONM-501 alone or in combination with immunotherapy for treating advanced solid tumors or lymphomas.
Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting
https://www.facingourrisk.org/research-clinical-trials/study/274/treatment-of-her2-positive-colorectal-cancer-as-first-line-treatment-in-the-metastatic-setting
Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting
This study is being done to decide if the drug Tukysa (Tucatinib) combined with other cancer drugs works better than the standard of care, which is chemotherapy treatment for people with a specific type of colorectal cancer called HER2 positive colorectal cancer. The study also aims to understand the side effects of the combination of these drugs in treatment. The combination of drugs being used are Tukysa (Tucatinib), Herceptin (Trastuzumab), and mFOLFOX6, which is a combination of Oxaliplatin, Leucovorin, Levoleucovorin, and Fluorouracil.
Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)
https://www.facingourrisk.org/research-clinical-trials/study/276/study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study
Treatment
Hispanic and Latino people diagnosed with colorectal cancer
The ENLACE study will learn more about colorectal cancer in Hispanic people so that treatment can be improved. Results may help your doctor choose your treatment and help you find out if you are eligible for a clinical trial. Your results may also help family members understand their cancer risks. People will have blood drawn and complete a questionnaire to join the study. Genetic testing will be done on your blood and the tissue from your tumor biopsy or surgery to test the genes that you inherited. You do not have to pay for the genetic testing. You will receive the results of your test from your oncologist and genetic counseling may be recommended. Two weeks and one year after talking with your doctor about your test results, you will complete follow-up questionnaires either in person or over the phone.
TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer
https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer
Treatment
Cancer treatment study for people with advanced solid tumors
The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.
Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor
https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor
Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy
The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.
Both nivolumab and relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.
Additional Results on Clinicaltrials.gov Treatment + Colorectal Cancer + Stage 4
58 results
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
NCT ID: NCT04329494 (https://clinicaltrials.gov/study/NCT04329494)
Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
NCT ID: NCT06130826 (https://clinicaltrials.gov/study/NCT06130826)
Stereotactic Ablative Radiotherapy (SABR) for the Treatment of Patients With Metastatic Cancer, ID-COMET Trial
NCT ID: NCT06563388 (https://clinicaltrials.gov/study/NCT06563388)
A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer
NCT ID: NCT05200442 (https://clinicaltrials.gov/study/NCT05200442)
Living Donor Liver Transplant for Unresectable Colorectal Liver Metastases
NCT ID: NCT05248581 (https://clinicaltrials.gov/study/NCT05248581)
A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
NCT ID: NCT06130280 (https://clinicaltrials.gov/study/NCT06130280)
Manipulation of the Gut Microbiome by a Standardized Preoperative Diet to Prevent Colorectal Cancer Recurrence and Metastasis Following Surgery
NCT ID: NCT06349590 (https://clinicaltrials.gov/study/NCT06349590)
First-Time-in-Human Study of GSK4381562 in Participants With Advanced Solid Tumors
NCT ID: NCT05277051 (https://clinicaltrials.gov/study/NCT05277051)
Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
NCT ID: NCT01365169 (https://clinicaltrials.gov/study/NCT01365169)
National Cancer Institute "Cancer Moonshot Biobank"
NCT ID: NCT04314401 (https://clinicaltrials.gov/study/NCT04314401)
Ultrasound and Photoacoustic Imaging for Enhanced Differential Diagnosis of Rectal Cancer
NCT ID: NCT04339374 (https://clinicaltrials.gov/study/NCT04339374)
Testing the Addition of Anti-cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment, Cetuximab Plus Encorafenib, for Colorectal Cancer
NCT ID: NCT06102902 (https://clinicaltrials.gov/study/NCT06102902)
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
NCT ID: NCT02838836 (https://clinicaltrials.gov/study/NCT02838836)
A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
NCT ID: NCT05592626 (https://clinicaltrials.gov/study/NCT05592626)
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
NCT ID: NCT05803382 (https://clinicaltrials.gov/study/NCT05803382)
A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://clinicaltrials.gov/study/NCT05086692)
Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
NCT ID: NCT05489211 (https://clinicaltrials.gov/study/NCT05489211)
GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
NCT ID: NCT04977453 (https://clinicaltrials.gov/study/NCT04977453)
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT ID: NCT06974110 (https://clinicaltrials.gov/study/NCT06974110)
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
NCT ID: NCT06885034 (https://clinicaltrials.gov/study/NCT06885034)
Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
NCT ID: NCT06300463 (https://clinicaltrials.gov/study/NCT06300463)
Phase I Trial of 5-Fluorouracil (5FU) -Based Therapy in Combination With Hydroxytyrosol (HT) in Patients With Advanced or Metastatic Colorectal Cancer
NCT ID: NCT06833866 (https://clinicaltrials.gov/study/NCT06833866)
Histotripsy Plus Chemotherapy vs Chemotherapy Alone for Advanced Colorectal Liver Metastasis
NCT ID: NCT07044362 (https://clinicaltrials.gov/study/NCT07044362)
Early Detection of Advanced Adenomas and Colorectal Cancer
NCT ID: NCT06342440 (https://clinicaltrials.gov/study/NCT06342440)
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT ID: NCT05691491 (https://clinicaltrials.gov/study/NCT05691491)
Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)
NCT ID: NCT06603818 (https://clinicaltrials.gov/study/NCT06603818)
Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
NCT ID: NCT05673148 (https://clinicaltrials.gov/study/NCT05673148)
PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma
NCT ID: NCT05286814 (https://clinicaltrials.gov/study/NCT05286814)
Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
NCT ID: NCT03965234 (https://clinicaltrials.gov/study/NCT03965234)
Minimal Residual Disease Assessment in Patients With Colorectal Cancer, the MiRDA-C Study
NCT ID: NCT04739072 (https://clinicaltrials.gov/study/NCT04739072)
Intravital Microscopy in Human Solid Tumors
NCT ID: NCT03823144 (https://clinicaltrials.gov/study/NCT03823144)
Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
NCT ID: NCT04668872 (https://clinicaltrials.gov/study/NCT04668872)
Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer
NCT ID: NCT06358677 (https://clinicaltrials.gov/study/NCT06358677)
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
NCT ID: NCT04701476 (https://clinicaltrials.gov/study/NCT04701476)
Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer
NCT ID: NCT06696768 (https://clinicaltrials.gov/study/NCT06696768)
Efficacy of Perioperative Opioid Sparing Techniques on Time to Initiation of Chemotherapy
NCT ID: NCT07153614 (https://clinicaltrials.gov/study/NCT07153614)
CPI-613 (Devimistat) in Combination With Hydroxychloroquine and 5-fluorouracil or Gemcitabine in Treating Patients With Advanced Chemorefractory Solid Tumors
NCT ID: NCT05733000 (https://clinicaltrials.gov/study/NCT05733000)
Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.
NCT ID: NCT07148128 (https://clinicaltrials.gov/study/NCT07148128)
Cryoablation Combined With Stereotactic Body Radiation Therapy for the Treatment of Painful Bone Metastases, the CROME Trial
NCT ID: NCT04693377 (https://clinicaltrials.gov/study/NCT04693377)
TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers
NCT ID: NCT04485013 (https://clinicaltrials.gov/study/NCT04485013)
PROGRESS: Precision Oncology Using Genomic Reflexive Evaluations for Study Selection and Survival
NCT ID: NCT06896162 (https://clinicaltrials.gov/study/NCT06896162)
An Observational Research Study to Uncover Subtypes of Cancer Cachexia
NCT ID: NCT06073431 (https://clinicaltrials.gov/study/NCT06073431)
Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
NCT ID: NCT04704661 (https://clinicaltrials.gov/study/NCT04704661)
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT ID: NCT05786924 (https://clinicaltrials.gov/study/NCT05786924)
Minimal Residual Disease Testing for the Early Detection of Cancer Recurrence in Resectable Stage II-IV Colorectal Cancer Patients
NCT ID: NCT07125729 (https://clinicaltrials.gov/study/NCT07125729)
Safety and Efficacy of NEO212 in Patients with Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
NCT ID: NCT06047379 (https://clinicaltrials.gov/study/NCT06047379)
ARGONAUT: Stool and Blood Sample Bank for Cancer Patients
NCT ID: NCT04638751 (https://clinicaltrials.gov/study/NCT04638751)
Pre- and Post-operative TEG Indices in Patients With or Without Adenocarcinoma Undergoing Surgical Resection
NCT ID: NCT05517811 (https://clinicaltrials.gov/study/NCT05517811)
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
NCT ID: NCT06654037 (https://clinicaltrials.gov/study/NCT06654037)
Testing Pump Chemotherapy in Addition to Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone for Patients With Unresectable Colorectal Liver Metastases: The PUMP Trial
NCT ID: NCT05863195 (https://clinicaltrials.gov/study/NCT05863195)
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
NCT ID: NCT04868877 (https://clinicaltrials.gov/study/NCT04868877)
Observational Basket Trial to Collect Tissue to Train and Validate a Live Tumor Diagnostic Platform
NCT ID: NCT05520099 (https://clinicaltrials.gov/study/NCT05520099)
Intraperitoneal Oxaliplatin and Fluorouracil for the Treatment of Patients with Peritoneal Metastases from Colorectal Cancer
NCT ID: NCT06269978 (https://clinicaltrials.gov/study/NCT06269978)
Predicting Response to Immune Checkpoint Inhibitors Across Solid Tumors Using a Live Tumor Diagnostic Platform
NCT ID: NCT06349642 (https://clinicaltrials.gov/study/NCT06349642)
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT ID: NCT05379985 (https://clinicaltrials.gov/study/NCT05379985)
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
NCT ID: NCT04899908 (https://clinicaltrials.gov/study/NCT04899908)
Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
NCT ID: NCT05239546 (https://clinicaltrials.gov/study/NCT05239546)
Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer
NCT ID: NCT06336902 (https://clinicaltrials.gov/study/NCT06336902)
About FORCE
FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.